作者 | 第一财经 钱小岩 时隔两年半后再次访华的盖茨，对中国和世界又有了新的认识。 时隔两年半后，盖茨基金会主席比尔·盖茨再次回到中国。 盖茨此次行程首先抵达中国海南，参观、了解中国在农业领域的创新进展，随后抵达上海，关注于传染 病防控和母婴健康，上述三大领域都是盖茨基金会（以下简称"基金会"）关注的重点。2月11日傍晚， 盖茨还意外在上海张江现身，出席一场名为"行动创造希望"的活动。 在行程间隙，盖茨接受了第一财经记者的专访。在专访中，盖茨就对华合作、人工智能潜力乃至围绕其 个人声誉的争议，都进行了坦诚和系统的回应。这是盖茨在2023年6月到访北京后的首次访华。在过去 30年中，盖茨到访中国20多次。 始终看好中国创新 "中国在过去三代人的时间里，积累了大量的农业发展和教育改善的经验，其实可以问问你们的祖父 母，在（中国）取得这些成功前，是什么样子的"，在专访伊始，盖茨就以此称赞中国在短期内实现现 代化的成绩。 盖茨对第一财经表示，中国正在大幅提升在农业研究方面的投入，对于在海南的参观，他对无融合生殖 杂交水稻印象深刻，"取得了难以置信的成果"。 2019年，美国科学家和中国农科院中国水稻研究所水稻生物学 ...

Core Viewpoint - The company is facing short-term performance pressure but is expected to drive innovation through self-research and transformation [1] Financial Performance - The company recently released a performance forecast for 2025, expecting a net loss attributable to shareholders of 66 million to 96 million yuan, and a non-recurring net loss of 79 million to 110 million yuan [1] - The performance pressure is primarily due to the impact of centralized procurement and the MAH system on the company's generic drug business [1] Strategic Initiatives - The company aims to optimize its business structure and return to a growth trajectory through active innovation [1] - A recent collaboration with Zhongshen Innovation on the self-researched oncology drug BIOS-0629 will provide the company with a milestone payment of 300 million yuan and a 10% share of the sales revenue [1] Long-term Outlook - Despite short-term performance challenges, the company's long-term development potential is considered significant [1] - The company’s insights into the industry and research capabilities are expected to lead to a second growth curve through innovative drug development and licensing [1] Earnings Forecast - The earnings per share (EPS) for 2025-2026 are projected to be -0.63 yuan and 0.37 yuan, respectively, down from previous estimates of 2.49 yuan and 2.80 yuan [1] - The EPS for 2027 is forecasted to be 0.61 yuan [1] Valuation - A DCF valuation method is employed, with a target price set at 53.84 yuan, maintaining a "buy" rating [1]

2025年公司通过与全球合作伙伴建立长期稳定的深度协作，商业项目按计划推进。（1）核心业务板块 保持稳健增长：DEL（包括DEL库的设计、合成和筛选及拓展应用）作为公司的基石业务报告期内保持 了稳步增长，且该业务保持了较高的毛利率，带来了利润的整体提升；与此同时，英国子公司进一步巩 固了FBDD/SBDD平台（基于分子片段与三维结构信息的药物发现技术）的稳步发展，主要业务板块收 入实现稳步增长的同时，DEL和FBDD/SBDD客户项目取得阶段性进展，均实现对应项目里程碑收入。 （2）新技术业务板块方面的商业转化逐步显现：OBT板块（基于寡核苷酸的药物研发平台）在持续拓 展传统核苷单体合成业务的同时，报告期内借助递送分子相关服务，实现了小核酸一站式项目的商业转 化，报告期内收入同比增长显著；报告期内公司自主设计并搭建的自动化高通量化学合成平台高效运 转，带动了ChemSer（基于小分子化学合成、平行合成等相关服务）收入的同比增长。公司主营业务收 入稳健增长及毛利率同步提升带来了本期利润增加。 格隆汇1月27日丨成都先导(688222.SH)公布，经公司财务部门初步测算，预计2025年年度实现归属于母 公司所有者 ...

Group 1 - The core viewpoint is that Hong Kong's development will be driven by three key engines: finance, innovation and technology, and trade [1][3] Group 2 - Hong Kong aims to enhance its advantages in the financial market by improving stock market competitiveness and attracting quality companies to list [3] - The government plans to diversify the financial market by exploring new opportunities in bulk commodity trading and international gold trading [3] - There is a focus on accelerating the development of a world-class innovation and technology hub, particularly in collaboration with cities in the Guangdong-Hong Kong-Macao Greater Bay Area [3] - The strategy includes attracting more world-class pharmaceutical companies and medical research institutions to establish a presence in Hong Kong, along with implementing a "first-tier approval" mechanism for drug and medical device registration [3] Group 3 - In terms of trade, Hong Kong will continue to play the role of a "super connector" and "super value adder" to support mainland Chinese enterprises in their international expansion [3] - The economic outlook for Hong Kong is positive, with expectations of moderate expansion in the global economy and continued support from mainland China and the broader Asian region [3] - Market expectations of interest rate cuts are anticipated to improve the business and investment climate [3]

以下文章来源于睿兽Pro ，作者Bestla 睿兽Pro . 创业邦旗下横跨一二级市场的科创数据平台。实时投资数据、追踪产业创新。找数据、做分析、链资 源，就上睿兽分析。 全球投融资周报 睿兽分析每周整理当周最值得关注的国内外热门投融资事件，帮助大家及时了解全球市场动向。 一级市场投融资概览 根据睿兽分析监测数据，本周国内一级市场披露的融资事件68个，与上周相比减少13个，其中已披 露融资金额的事件44个，总融资规模为124.69亿元人民币，平均融资金额为2.83亿元人民币。 行业分布 从融资事件数量来看，本周智能制造、人工智能、医疗健康领域融资最活跃。分别为智能制造22 个、人工智能15个、医疗健康10个。 从已披露金额事件的融资规模来看，汽车交通最高，融资总规模约为61.52亿元人民币。其中新能源 汽车研发生产商「长安新能源」完成61.22亿人民币C轮融资。 深蓝汽车科技有限公司，前身为重庆长安新能源汽车科技有限公司，是一家专注于新能源汽车领域的 全产业链企业。公司致力于通过技术创新，打造全场景智慧出行的解决方案，满足用户对高品质、智 能化出行体验的需求。 其次是智能制造行业，已披露融资总额为22.33亿 ...

Core Viewpoint - The report highlights the strong performance of structural innovation in the healthcare sector, particularly in CXO and innovative drugs, while blood products, retail pharmaceuticals, vaccines, and IVD indices have seen declines [1]. Summary by Categories Innovation in Pharmaceuticals - The focus is on innovative drugs, particularly companies with strong commercialization capabilities and rich pipelines in BioPharma and Pharma, as well as cutting-edge technologies like gene therapy and small nucleic acids [1]. Medical Devices - The medical device sector is expected to see opportunities post-2025 after inventory clearance, with a focus on endoscopy and robotics. Innovative consumables in neurointervention and peripheral intervention are also highlighted as key areas supported by national policies [1]. Domestic Consumption in Pharmaceuticals - Companies related to domestic consumption in the pharmaceutical sector are expected to benefit from policies emphasizing domestic demand, as outlined in the Central Economic Work Conference [1]. External Demand Recovery - Following the Federal Reserve's interest rate cuts and the passage of the new Biosecurity Act in the House, uncertainties in policies are expected to diminish, leading to a potential recovery in overseas orders for external demand-oriented CXO companies, which may alleviate valuation pressures in the sector [1]. Vaccine ETF - The Vaccine ETF (159643) tracks the Vaccine Biotechnology Index (980015), which selects listed companies involved in vaccine research, production, and sales, reflecting the overall performance of the biotechnology sector, particularly in vaccines. This index focuses on bioproducts and medical research, showcasing high growth and innovation potential, making it suitable for investors interested in the biopharmaceutical industry [1].

Group 1 - The third China Overseas Intelligence Development Conference was held in Fuzhou from December 1 to 3, attracting over a thousand experts and representatives from 39 countries and regions [1] - The conference focused on promoting talent cooperation in the marine economy and signed six cooperation projects in agriculture and forestry, facilitating over 100 technology cooperation projects and 300 talent introduction intentions [1] - The event expanded 20 overseas talent service stations and promoted 450 high-tech achievements [1] Group 2 - The conference featured the release of the 2025 Fuzhou Overseas Intelligence "Ranking List," which included a technology demand list of 10 items [2] - A project utilizing MRI and diagnostic reports to generate postoperative pathological indicators for liver cancer was successfully unveiled by Fujian Medical University Wu Mengchao Memorial Hospital [2] - The research team for the liver cancer project has collected over 2,000 clinical data cases and aims to complete the development within two to three years [3] Group 3 - The talent introduction and industry support policies in Fujian are considered attractive and competitive, as evidenced by international participants seeking collaboration [4] - The conference facilitated connections between startups and investors, providing comprehensive support for technology innovation and entrepreneurship [4] - An online platform named "Qiaozhi Hui" was launched to continuously track and promote the outcomes of the conference [4]

Group 1 - Seres Group plans to list on the Hong Kong Stock Exchange with a maximum issue price of HKD 131.50 per share, aiming for a total issuance scale of approximately USD 1.7 billion [1] - If priced at HKD 131.50, Seres' market capitalization will reach approximately HKD 215 billion, positioning it alongside other new energy vehicle companies like NIO and Li Auto [1] Group 2 - Huawei's Yu Chengdong has been appointed as the head of the Product Investment Committee while continuing his roles as Executive Director and Chairman of the Terminal BG [2] - Huawei's Pura 80 Ultra and Watch GT 6 Pro have been recognized in Time magazine's list of the best inventions of 2025, highlighting their innovative features [5] Group 3 - "Honor of Kings" has surpassed 139 million daily active users and over 260 million monthly active users globally [3] Group 4 - Following Microsoft's termination of support for Windows 10, the global PC market saw an 8.1% year-on-year growth in Q3, driven by users upgrading to Windows 11 and companies stockpiling to mitigate tariff risks [4] - Lenovo led the market with a 17.4% increase in shipments, while Apple Mac sales grew by 14.9%, making it the second-largest beneficiary [4] Group 5 - NIO announced that its battery swap service has surpassed 90 million swaps, achieving this milestone in just 100 days from the 80 million mark, with an average of over 100,000 swaps per day [7] Group 6 - Two multinational medical giants, AstraZeneca and Medtronic, have announced the establishment of new R&D centers in Beijing, reinforcing China's position as a global hub for medical innovation [8] Group 7 - ByteDance is reportedly developing a new game distribution platform called GameTop, similar to Steam, aimed at providing diverse gaming content and social spaces for overseas users [6]

Core Viewpoint - Baicheng Pharmaceutical (301096.SZ) is currently experiencing a decline in stock price, closing at 57.29 yuan with a drop of 3.13%, indicating it is in a state of underperformance since its IPO [1] Group 1: Company Overview - Baicheng Pharmaceutical was listed on the Shenzhen Stock Exchange's ChiNext board on December 20, 2021, with an initial issuance of 27.0417 million shares at a price of 79.60 yuan per share [1] - The stock reached a peak price of 120 yuan on its first trading day, marking the highest price since its listing [1] Group 2: Financial Performance - The total funds raised from the initial public offering (IPO) amounted to 2.153 billion yuan, with a net amount of 1.863 billion yuan after deducting issuance costs [1] - The actual net funds raised exceeded the original plan by 1.213 billion yuan, as the company initially aimed to raise 651 million yuan for its headquarters and R&D center project [1] - The total issuance costs for the IPO were 289 million yuan, including underwriting and sponsorship fees of 262 million yuan [1]

Core Viewpoint - The company has completed the acquisition of a property in Irvine, California, for $4.365 million, and established a wholly-owned subsidiary, ETHK BANK, to enhance its operations in the North American market, focusing on stablecoin and intellectual property securitization [1][2]. Group 1: Property Acquisition - The acquired property, located at 9840 Irvine Center Drive, spans approximately 4,960 square feet and includes a two-story office building of about 9,920 square feet, designed for both office and research purposes [2]. - This property will serve as the company's strategic headquarters in the U.S., supporting the development of stablecoin public chain technology and intellectual property securitization, creating a hub for connecting global innovative assets with capital markets [2]. Group 2: ETHK BANK - ETHK BANK will act as the global operational platform for the company's stablecoin and intellectual property securitization business, managing core business directions including stablecoin licensing and compliance framework establishment [3]. - The company is pursuing a federal payment stablecoin issuer license under the U.S. GENIUS Act and plans to apply for a national trust bank license to create a compliant operational system [3]. - The company is developing an innovative stablecoin architecture that supports the generation of stablecoins pegged to the U.S. dollar through real-world asset collateral, aiming to provide a transparent and sustainable digital asset yield solution [3]. Group 3: Key Project Cooperation - The company has signed a strategic cooperation agreement with Transcenta Holding Limited for the tokenization of innovative drug pipeline assets valued at approximately $1.5 billion, with ETHK BANK leading the initiative [5]. - This project focuses on cutting-edge research in cancer treatment, providing a transparent and professional channel for global investors to access medical assets [5]. Group 4: Future Outlook - The acquisition of the U.S. property and the establishment of ETHK BANK signify the company's strategic upgrade towards becoming a global leader in stablecoin and high-tech intellectual property capital operations [6]. - The company aims to integrate on-chain financial infrastructure with the real economy, aligning with global digital economy trends and potentially opening new growth pathways [6]. - The board believes these initiatives reflect the company's core philosophy of transforming knowledge into capital, ensuring long-term stable returns for shareholders through compliant capital operations and innovative practices [6].